HIV, Human Immunodeficiency Virus
Conditions
Brief summary
The purpose of this study is to determine the safety and bioactivity of an herbal supplement called kansui, which contains several active ingredients such as ingenols that may have a role in helping clear HIV from the body. Kansui has been used in traditional Chinese medicine for centuries to treat various ailments such as for eliminating excess fluid in the abdomen or lungs, loosening phlegm from the chest, and relieving constipation. Based on preliminary in vitro data from our group, kansui extract powder is a potent activator of HIV transpcription in latently infected Jurkat cells. The investigators' hypothesis is that kansui extract powder prepared as tea will be safe and well-tolerated, elicit an in vivo immunologic response, and at the doses administered, increase HIV transcription in latently-infected cells among HIV-infected patients on suppressive antiretroviral therapy.
Detailed description
Millions HIV-infected individuals are now receiving life-saving antiretroviral therapy (ART). However, mortality remains high, particularly in resource-limited countries. Chronic HIV-infected individuals demonstrate evidence of persistent immune activation despite ART, which is an independent predictor of mortality in this setting. Given the current absence of an effective HIV vaccine, finding a cure for HIV will have a large impact on the long-term health of treated HIV-infected individuals. The key challenge of HIV eradication strategies is the persistence of a small pool of resting memory CD4+ T cells that harbor latent replication-competent HIV, untouched by current ART. One potential strategy to eliminate this reservoir in a shock and kill approach in which latency reactivating agents (LRAs) are used to shock the virus out of these cells in order for the host immune response, ART, and/or additional immunomodulatory agents to then kill the virus-expressing cells. The goal of the current study is to evaluate the safety and in vivo biological response to an herbal supplement used in traditional Chinese medicine (kansui) that has potent in vitro latency reactivating capabilities. Kansui is an inexpensive, readily available herbal supplement prescribed for thousands of years in traditional Chinese medicine and contains active compounds such as ingenols that have been shown to reverse latency in an animal model. A semi-synthetic form of ingenol has been shown to potently reactivate latent simian immunodeficiency virus (SIV) in rhesus macaques and is currently undergoing early drug development. Though kansui has been studied extensively in traditional Chinese medicine, this herbal supplement has never been evaluated for biologic activity in HIV disease using Western scientific research methods. This pilot clinical trial will generate preliminary results regarding the safety and in vivo biologic activity of kansui. Promising results from this study may allow future larger studies which can evaluate the efficacy of this non-pharmacologic agent in the treatment of HIV disease.
Interventions
DRUGEuphorbia kansui extract powder prepared as tea
1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
Sponsors
University of Utah
amfAR, The Foundation for AIDS Research
University of California, San Francisco
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Confirmed HIV-1 infection in adults aged 18 years or older. 2. Continuous therapy with a DHHS recommended/alternative combination ART for least 36 months (at least 3 agents) at study entry with no regimen changes in the preceding 24 weeks. 3. Maintenance of undetectable plasma HIV-1 RNA (\<40 copies/ml) for at least 36 months. Episodes of single HIV plasma RNA 50-500 copies.ml will not exclude participation if subsequent HIV plasma RNA is \<40 copies/ml. 4. Two CD4+ T cell counts \>350 cells/μl in the six months prior to screening.
Exclusion criteria
1. Pre-ART viral load \<2000 copies/ml (HIV controllers) 2. Based on prior history and/or virologic testing, no alternative ART regimens are available in the event that the current ART regimen is compromised as a result of this study. 3. Recent hospitalization in the last 90 days. 4. Recent infection in the last 90 days requiring systemic antibiotics. 5. Recent vaccination within the last 8 weeks prior to study scree or any study blood draw. 6. Any known history of liver-related diseases including but not limited to: hepatic cirrhosis of decompensated chronic liver diseases; clinically active hepatitis B or C infection as evidenced by clinical jaundice or Grade 2 or higher liver function test abnormalities; any hepatic impairment, regardless of the graded liver function test abnormalities. 7. Any known history of gastrointestinal diseases including but not limited to: history of diarrheal illness requiring the use of anti-motility agents including inflammatory bowel disease, chronic diarrhea not otherwise specified; history of gastrointestinal bleeding with hemoglobin below 12.5 g/dL; history of gastric or duodenal ulcers; inflammatory gastrointestinal disease such as Crohn's disease or ulcerative colitis 8. Any renal disease (eGFR \< 90 ml/min) or acute nephritis. 9. Screening hemoglobin below 12.5 g/dL. 10. Screening TSH consistent with hypothyroidism. 11. Significant myocardial disease (current myocarditis or reduced left ventricular ejection fraction below the lower limit of normal) or diagnosed coronary artery disease. 12. Significant respiratory disease requiring oxygen. 13. Diabetes or current hypothyroidism. 14. Participants of reproductive potential or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test at screening. All participants of childbearing potential must agree to use a double-barrier method of contraception throughout the study period and up to 90 days after the last dose of kansui. 15. Exposure to any immunomodulatory drug (including maraviroc) in the16 weeks prior to study. 16. Prior or current use of experiment agents used with the intent to perturb the HIV-1 viral reservoir. 17. History of seizures, psychosis, abnormal electroencephalogram or brain damage with significant persisting neurological deficit 18. Positive test for tuberculosis by either skin test (PPD) or blood interferon-gamma release assay (QuantiFERON). 19. Significant substance use, which in the opinion of the investigator(s), is likely to interfere with the conduct of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of Euphorbia Kansui Extract Powder Prepared as Tea Assessed by the Number of Grade 2 or Higher Severity Adverse Events or Drug-related Laboratory Abnormalities That Exceed a Frequency of 5% | 31 days | The number of grade 2 or higher severity adverse events (AEs) or drug-related laboratory abnormalities that exceed a frequency of 5% over a 31 day study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Early T Cell Immune Activation (Change in Percent CD69+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Baseline and 9 days | The change in early immune activation levels (as measured by the Change in Percent CD69+ CD4+ and CD8+ T cells) over a 9 day study period. |
| T Cell Immune Activation (Change in Percent CD38+HLA-DR+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Baseline and 9 days | The change in immune activation levels (as measured by the percent change in CD38+HLADR+ CD4+ and CD8+ T cells) over a 9 day study period. |
| HIV Reservoir Size (Change in HIV RNA Pol Levels in Copies/ug From Baseline to 9 Days) | Baseline and 9 days | The change in HIV reservoir size (as measured by cell-associated unspliced ddPCR HIV RNA Pol levels in copies/ug) over a 9 day study period. |
| HIV Reservoir Size (Plasma HIV RNA Level From Baseline to 9 Days) | Baseline and 9 days | The change in HIV reservoir size (as measured by ultra-sensitive plasma HIV RNA levels) over a 9 day study period. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Kansui 1g Per Day x 1 Day Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
Euphorbia kansui extract powder prepared as tea: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily | 2 |
| Kansui 1g Per Day x 2 Days Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
Euphorbia kansui extract powder prepared as tea: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily | 0 |
| Kansui 1g Per Day x 3 Days Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
Euphorbia kansui extract powder prepared as tea: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily | 1 |
| Placebo 1g Per Day x 1 Day Study participants will be given 1 g of placebo prepared as tea for a total of 1 daily dose. | 0 |
| Placebo 1g Per Day x 2 Days Study participants will be given 1 g placebo prepared as tea for a total of 2 consecutive daily doses. | 0 |
| Placebo 1g Per Day x 3 Days Study participants will be given 1 g of placebo prepared as tea for a total of 3 consecutive daily doses. | 2 |
| Total | 5 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | The study was terminated (Halted Prematurely). | 0 | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Kansui 1g Per Day x 1 Day | Kansui 1g Per Day x 3 Days | Placebo 1g Per Day x 3 Days | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 1 Participants | 2 Participants | 5 Participants |
| Age, Continuous | 43.7 years STANDARD_DEVIATION 6.4 | 56 years STANDARD_DEVIATION 0 | 55.1 years STANDARD_DEVIATION 4.4 | 49 years STANDARD_DEVIATION 9.1 |
| CD4 T Cell Count | 914 cells/uL STANDARD_DEVIATION 359.7 | 428 cells/uL STANDARD_DEVIATION 0 | 745.5 cells/uL STANDARD_DEVIATION 225.6 | 732.1 cells/uL STANDARD_DEVIATION 333.1 |
| HIV VL<40 | 2 Participants | 1 Participants | 2 Participants | 5 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 1 Participants | 2 Participants | 4 Participants |
| Region of Enrollment United States | 2 participants | 1 participants | 2 participants | 5 participants |
| Sex: Female, Male Female | 1 Participants | 0 Participants | 1 Participants | 2 Participants |
| Sex: Female, Male Male | 1 Participants | 1 Participants | 1 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 2 | 0 / 0 | 0 / 1 | 0 / 0 | 0 / 0 | 0 / 2 |
| other Total, other adverse events | 0 / 2 | 0 / 0 | 0 / 1 | 0 / 0 | 0 / 0 | 0 / 2 |
| serious Total, serious adverse events | 0 / 2 | 0 / 0 | 0 / 1 | 0 / 0 | 0 / 0 | 0 / 2 |
Outcome results
Primary
Safety of Euphorbia Kansui Extract Powder Prepared as Tea Assessed by the Number of Grade 2 or Higher Severity Adverse Events or Drug-related Laboratory Abnormalities That Exceed a Frequency of 5%
The number of grade 2 or higher severity adverse events (AEs) or drug-related laboratory abnormalities that exceed a frequency of 5% over a 31 day study period.
Time frame: 31 days
Population: The study was terminated (Halted Prematurely).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Kansui 1g Per Day x 1 Day | Safety of Euphorbia Kansui Extract Powder Prepared as Tea Assessed by the Number of Grade 2 or Higher Severity Adverse Events or Drug-related Laboratory Abnormalities That Exceed a Frequency of 5% | 0 Participants |
| Kansui 1g Per Day x 2 Days | Safety of Euphorbia Kansui Extract Powder Prepared as Tea Assessed by the Number of Grade 2 or Higher Severity Adverse Events or Drug-related Laboratory Abnormalities That Exceed a Frequency of 5% | 0 Participants |
| Kansui 1g Per Day x 3 Days | Safety of Euphorbia Kansui Extract Powder Prepared as Tea Assessed by the Number of Grade 2 or Higher Severity Adverse Events or Drug-related Laboratory Abnormalities That Exceed a Frequency of 5% | 0 Participants |
| Placebo 1g Per Day x 1 Day | Safety of Euphorbia Kansui Extract Powder Prepared as Tea Assessed by the Number of Grade 2 or Higher Severity Adverse Events or Drug-related Laboratory Abnormalities That Exceed a Frequency of 5% | 0 Participants |
| Placebo 1g Per Day x 2 Days | Safety of Euphorbia Kansui Extract Powder Prepared as Tea Assessed by the Number of Grade 2 or Higher Severity Adverse Events or Drug-related Laboratory Abnormalities That Exceed a Frequency of 5% | 0 Participants |
| Placebo 1g Per Day x 3 Days | Safety of Euphorbia Kansui Extract Powder Prepared as Tea Assessed by the Number of Grade 2 or Higher Severity Adverse Events or Drug-related Laboratory Abnormalities That Exceed a Frequency of 5% | 0 Participants |
Secondary
Early T Cell Immune Activation (Change in Percent CD69+ CD4+ and CD8+ T Cells From Baseline to 9 Days)
The change in early immune activation levels (as measured by the Change in Percent CD69+ CD4+ and CD8+ T cells) over a 9 day study period.
Time frame: Baseline and 9 days
Population: The study was terminated (Halted Prematurely). We do not have data for the last participant in placebo 1g per day x 3 days group.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Kansui 1g Per Day x 1 Day | Early T Cell Immune Activation (Change in Percent CD69+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD69+ CD4+ T Cells | -0.175 percentage of T cells | Standard Deviation 0.445 |
| Kansui 1g Per Day x 1 Day | Early T Cell Immune Activation (Change in Percent CD69+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD69+ CD8+ T Cells | 0 percentage of T cells | Standard Deviation 0.608 |
| Kansui 1g Per Day x 3 Days | Early T Cell Immune Activation (Change in Percent CD69+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD69+ CD4+ T Cells | 0.5 percentage of T cells | Standard Deviation 0 |
| Kansui 1g Per Day x 3 Days | Early T Cell Immune Activation (Change in Percent CD69+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD69+ CD8+ T Cells | -2.1 percentage of T cells | Standard Deviation 0 |
| Placebo 1g Per Day x 3 Days | Early T Cell Immune Activation (Change in Percent CD69+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD69+ CD8+ T Cells | 5.7 percentage of T cells | Standard Deviation 0 |
| Placebo 1g Per Day x 3 Days | Early T Cell Immune Activation (Change in Percent CD69+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD69+ CD4+ T Cells | 7.49 percentage of T cells | Standard Deviation 0 |
Secondary
HIV Reservoir Size (Change in HIV RNA Pol Levels in Copies/ug From Baseline to 9 Days)
The change in HIV reservoir size (as measured by cell-associated unspliced ddPCR HIV RNA Pol levels in copies/ug) over a 9 day study period.
Time frame: Baseline and 9 days
Population: The study was terminated (Halted Prematurely). We do not have data for the last participant in placebo 1g per day x 3 days group.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Kansui 1g Per Day x 1 Day | HIV Reservoir Size (Change in HIV RNA Pol Levels in Copies/ug From Baseline to 9 Days) | -0.17 copies/ug | Standard Deviation 0.24 |
| Kansui 1g Per Day x 3 Days | HIV Reservoir Size (Change in HIV RNA Pol Levels in Copies/ug From Baseline to 9 Days) | -59.9 copies/ug | Standard Deviation 0 |
| Placebo 1g Per Day x 3 Days | HIV Reservoir Size (Change in HIV RNA Pol Levels in Copies/ug From Baseline to 9 Days) | -10.9 copies/ug | Standard Deviation 0 |
Secondary
HIV Reservoir Size (Plasma HIV RNA Level From Baseline to 9 Days)
The change in HIV reservoir size (as measured by ultra-sensitive plasma HIV RNA levels) over a 9 day study period.
Time frame: Baseline and 9 days
Population: The study was terminated (Halted Prematurely). We do not have data for the last participant in placebo 1g per day x 3 days group.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Kansui 1g Per Day x 1 Day | HIV Reservoir Size (Plasma HIV RNA Level From Baseline to 9 Days) | -128.6 copies/ug | Standard Deviation 139.44 |
| Kansui 1g Per Day x 3 Days | HIV Reservoir Size (Plasma HIV RNA Level From Baseline to 9 Days) | 56 copies/ug | Standard Deviation 0 |
| Placebo 1g Per Day x 3 Days | HIV Reservoir Size (Plasma HIV RNA Level From Baseline to 9 Days) | -68.8 copies/ug | Standard Deviation 0 |
Secondary
T Cell Immune Activation (Change in Percent CD38+HLA-DR+ CD4+ and CD8+ T Cells From Baseline to 9 Days)
The change in immune activation levels (as measured by the percent change in CD38+HLADR+ CD4+ and CD8+ T cells) over a 9 day study period.
Time frame: Baseline and 9 days
Population: The study was terminated (Halted Prematurely). We do not have data for the last participant in placebo 1g per day x 3 days group.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Kansui 1g Per Day x 1 Day | T Cell Immune Activation (Change in Percent CD38+HLA-DR+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD38+HLA-DR+ CD4+ T Cells | 0.05 percentage of T cells | Standard Deviation 0.03 |
| Kansui 1g Per Day x 1 Day | T Cell Immune Activation (Change in Percent CD38+HLA-DR+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD38+HLA-DR+ CD8+ T Cells | 0.5 percentage of T cells | Standard Deviation 0.72 |
| Kansui 1g Per Day x 3 Days | T Cell Immune Activation (Change in Percent CD38+HLA-DR+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD38+HLA-DR+ CD4+ T Cells | -0.11 percentage of T cells | Standard Deviation 0 |
| Kansui 1g Per Day x 3 Days | T Cell Immune Activation (Change in Percent CD38+HLA-DR+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD38+HLA-DR+ CD8+ T Cells | -0.3 percentage of T cells | Standard Deviation 0 |
| Placebo 1g Per Day x 3 Days | T Cell Immune Activation (Change in Percent CD38+HLA-DR+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD38+HLA-DR+ CD4+ T Cells | 0.03 percentage of T cells | Standard Deviation 0 |
| Placebo 1g Per Day x 3 Days | T Cell Immune Activation (Change in Percent CD38+HLA-DR+ CD4+ and CD8+ T Cells From Baseline to 9 Days) | Change in Percent CD38+HLA-DR+ CD8+ T Cells | 0.2 percentage of T cells | Standard Deviation 0 |